Rotating dexamethasone and methylprednisolone can help to alleviate dexamethasone-induced hiccups (DIH) without the loss of antiemetic effects in patients undergoing chemotherapy.
Drug treatment rather than observation may delay disease progression and extend survival in persons with high-risk smoldering multiple myeloma, according to recent study results.
Dexamethasone is more effective for reducing cancer-related fatigue; patients show improvements in QoL and physical distress.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
Imaging studies and laboratory tests were negative, but lumbar puncture revealed the cause of this patient's unexplained neurologic symptoms.
Prognosis is not good, but many patients still seek treatment, equating prolonged neurologic function with better quality of life.
Combining lenalidomide with low-dose rather than high-dose dexamethasone for the treatment of multiple myeloma improves survival and lowers toxicity, according to the results of a controlled trial
Multiple myeloma patients experience high response rates when treated with a drug regimen consisting of 3 drugs, according to data presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|